Fuyuan Pharmaceutical’s wholly-owned subsidiary, Bifonazole Solution, has been approved for registration
August 3, 2025
Source: drugdu
42
On July 30, Fuyuan PharmaceuticalDisclosure of the announcement regarding the receipt of the Drug Registration Certificate for Bifonazole Solution. Recently, the company's wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., received the Drug Registration Certificate (Certificate No.: 2025S02274) for Bifonazole Solution (Specification: 1% (10 ml: 0.1 g)) from the National Medical Products Administration, approving the production of the drug.
This drug is used to treat the following fungal skin diseases: (1) Tinea pedis: Tinea pedis of the feet, body, and thighs. (2) Candidiasis: Interdigital erosions, intertrigo, and cutaneous candidiasis. (3) Vitiligo.
Fuyuan Pharmaceutical received the application acceptance notice for its bifonazole solution on January 12, 2024, and recently received approval from the National Medical Products Administration (NMPA). According to relevant national policies and regulations, obtaining this Drug Registration Certificate is equivalent to passing the consistency evaluation, which will further enrich the company's product line and help enhance the market competitiveness of its products.
Source：https://finance.eastmoney.com/a/202507313472650037.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- After the impact of centralized procurement, this old pharmaceutical company gambled heavily on research and development August 20, 2025
- Zhifei Biological has turned from profit to loss, and the transformation and breakthrough of domestic vaccines have become a trend August 20, 2025
- The subsequent R&D nodes and external licensing expectations of the innovative vaccine pipeline are worth paying attention to August 20, 2025
- Zhifei Bio’s subsidiary’s vaccine application for clinical trial accepted August 20, 2025
- Seven blood metabolites associated with excessive daytime sleepiness August 20, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
